Corporate overview
-A global company with over 50 years of history in the development, manufacturing, and sales of blood purification　products
-Provides unique, high-value-added products in the stable dialysis business
-Maintains the No.1 market share in Japan’s apheresis business for intractable disease treatment and secures high market share in growing overseas markets
-Develops new products and services that benefit patients and healthcare professionals, including CryoSeal and new businesses in intensive care areas

Investment overview
Carve-out, Share purchase
Integral Fund V and Principal Investment
Investment period: from April 2025

Integral management support
-Dispatch of directors, auditor and full-time member to support implementing investment themes
-Support to strengthen new businesses and overseas expansion by leveraging Integral’s network